56 related articles for article (PubMed ID: 15726535)
1. Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian Cancer.
Levit SL; Tang C
Nanomaterials (Basel); 2021 Apr; 11(4):. PubMed ID: 33923947
[TBL] [Abstract][Full Text] [Related]
2. Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer.
Huang CY; Cheng M; Lee NR; Huang HY; Lee WL; Chang WH; Wang PH
Int J Environ Res Public Health; 2020 Mar; 17(7):. PubMed ID: 32224896
[TBL] [Abstract][Full Text] [Related]
3. How to mathematically optimize drug regimens using optimal control.
Moore H
J Pharmacokinet Pharmacodyn; 2018 Feb; 45(1):127-137. PubMed ID: 29411198
[TBL] [Abstract][Full Text] [Related]
4. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
Krivak TC; Darcy KM; Tian C; Armstrong D; Baysal BE; Gallion H; Ambrosone CB; DeLoia JA;
J Clin Oncol; 2008 Jul; 26(21):3598-606. PubMed ID: 18640939
[TBL] [Abstract][Full Text] [Related]
5. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
7. Maintenance or consolidation therapy in advanced ovarian cancer.
Pectasides D; Pectasides E
Oncology; 2006; 70(5):315-24. PubMed ID: 17164587
[TBL] [Abstract][Full Text] [Related]
8. Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.
Muggia FM
Semin Oncol; 2004 Dec; 31(6 Suppl 15):19-24. PubMed ID: 15726535
[TBL] [Abstract][Full Text] [Related]
9. Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103.
Markman M
J Exp Ther Oncol; 2004 Jul; 4(2):131-6. PubMed ID: 15500007
[TBL] [Abstract][Full Text] [Related]
10. Perspectives in the treatment of colorectal cancer.
Ozer H; Diasio RB
Semin Oncol; 2004 Dec; 31(6 Suppl 15):14-8. PubMed ID: 15726534
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
